Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Something smells? If Bavi is performing as expected and Docetaxel is "miraculously" producing results never seen "out of left field", something smells.
You don't just have a drug that has been administered for years and you know the expected outcome and suddenly outperform the historic norm.
That is like filling up your gas tank where you normally get 30 mi/gal and then all of the sudden you are getting 50 mi/gal meanwhile, it is the same fuel you have been using for the last 5 years from the same gas station. Or is it???????
Something smells really bad....AGAIN!!
I wanted to ask some of the Docs on this board a question in stepping away from different forms of cancer.
Could we see that Bavi could be used in conjunction to treat MS?
Quick question. Did Dr. Allison Stopeck publish her Breast Cancer paper, the one we ha e been awaiting for review?
6B for all regions for partner. That would be my guess.
I thought he said HER2
AF will be done in coming years. Karma is a bitch and this is not just the PPHM folks. The wealthy will bury him soon with all his BS. Btw, who gives a flying piss what he says or said.
Important...really important.
Was their any discrepancies released during that 22 day period between
Dec. 29, 2011 and Jan. 20, 2012?
Thx. I just saw that. Does anyone remember any issues or additional information released between Dec. 29, 2011 and Jan. 20, 2012?
This is a period of 22 days. Curious if anything else came about after initial results. IMPORTANT.
When were the initial results for HEP C released? 2012? If so, what date?
Hysterical!! Certainly my favorite post of 2015.
Here we go this morning. The beginning of the climb.
3 months
On 1 share.
Very interesting article. Thanks for posting. I had someone mention this to me back fall of '13. I didn't believe it would remotely happen, but it looks like steps are being taken to treat patients expeditiously. I would have liked to have seem PP in there, but either way...combinations with those downstream players will be key. Bavi doesn't discriminate. Oh yeah, we have so called "collaborations" with AZ and DNA...maybe we are "in play" here as well.
please provide any significant update(s). Some us cannot join due to limit size. How many connections do they allow?
same here...I am trying from mobile device now.
http://www.fiercepharma.com/story/cancer-drugs-beware-docs-get-monthly-paybacks-sticking-preferred-meds/2014-05-28?utm_medium=nl&utm_source=internal
"Payers have decided that formularies aren't enough, at least for cancer drugs. As The Wall Street Journal reports, insurers are revamping their reimbursement protocols to strip incentives for pricey meds--and introduce new ones for "preferred" treatments.
WellPoint, one of the biggest U.S. payers, is planning a radical shift in reimbursement. The insurer will offer oncologists a $350-per-month incentive to use its recommended regimens. Doctors will win the reward for each patient put on WellPoint's chosen treatment plans. The cash could quickly add up for busy oncologists.
And the losses could quickly add up for drugmakers not fortunate enough to be part of those recommended regimens. It's the formulary approach on steroids. WellPoint could use those recommendations as leverage to win lower prices from pharma companies--and to shut out meds it deems overpriced."
Just one more hurdle to have to overcome...amazing! Could this help or hurt us once we have approval? Hence, another reason why a partnership with heavy lobbying becomes even more important. IMHO.
Thanks for sharing this Stage 4 blog.
replying to a 2006 post. Thought it would be helpful to post as it was PUBLIC RELEASED in 2010. Could not find this posted anywhere with your excellent tracking/posting timelines. Thought you could add to list.
http://www.dtic.mil/dtic/tr/fulltext/u2/a524416.pdf
Unemon-- answer this please?
Why do you post the following on your twitter?
http://unemon.com/ResearchEasy/20140204_PPHM.html
if you are LONG PPHM in this article...why continue to piss people off? is it for sh^ts and giggles? if so, do not see the angle on wanting people to put you on ignore.
Happy Easter!
Pfizer approached Aztrazeneca for100B. Turned down though...13B higher than market cap...
http://mobile.reuters.com/article/idUSL6N0NC0AV20140420?irpc=932
Offers are out there people...but all around the right.
Listening to webcast right now. But found the following today.
http://medicalxpress.com/news/2014-03-big-science-uncovers-piece-alzheimer.html
"The experiments revealed that the peptide that makes up Alzheimer's lesions is capable of converting iron into the form which could be causing damage to brain cells. This means that the lesions caused by Alzheimer's could be causing a subtle disruption in how the brain manages iron, confronting brain cells with a level of toxicity that they simply cannot manage.
This discovery paves the way for future medical research into treatments that could halt or manage the conversion of iron into this toxic form, potentially slowing or limiting the damage to the brain."
Wook- You should contact iHub and just ask it for this board. Tell them it would help IR funnel through messages more quickly
,,,and even me!
You would be providing humanity with logic and time management.
"ihub admin...it is just a button...
damn it the facebook!!!
Because it is about money. iHub would want to charge you to "like".
They want to charge you for private messaging...sorry fellas, no PM
$$$...funny, I wont pay the additional 1/10000$ for features on ihub, but I will spend the money on nice wine. which one benefits me more. Marinating the liver...Priorities...ha!!
Delete
I received similar update(s) and I was not present. CP is just kind enough to post. There a few here that I know heard/received same info bidrite and CP posted.
I believe it was sushi for dinner.
I hear ya. But the transcript is on the internet and anybody who wants to question can go and review to confirm what was really sent and what wasn't. I believe I saw that on YMB as well. That board is absolutely silly except for a few. It is what it is. Anyone wanting to invest major $$$ will know that the first dosing has occurred, no matter what was posted to that board. IMO.
Not to beat a dead horse...
http://seekingalpha.com/article/2075263-peregrine-pharmaceuticals-management-discusses-q3-2014-results-earnings-call-transcript
SHAN:
"To that end, we have accomplished a great deal during this past quarter, as the first clinical sites were initiated and with patients already enrolled and being dosed. We also remain on track with our regulatory and ethics approval timeline for rolling out European and Asian-Pacific sites over the next few months."
"Another highlight of the quarter was the receipt of Fast Track designation from the U.S. FDA for the combination of bavituximab and docetaxel to improve overall survival in patients with previously treated non-squamous, non-small cell lung cancer compared to docetaxel alone, which is the indication being examined in the SUNRISE trial. This designation facilitates the development and the review of marketing applications for promising drugs like bavituximab, which are intended to treat serious or life-threatening conditions for indications of unmet medical need."
Had to register at NYAS.
LOL...everything is cyclic. :)
Noted! Your contribution is also helpful to others (including "me") and yep, I could choose to ignore you...but I also find your posts worthwhile...you can do the same...maybe you should follow that with putting others on "ignore".
but continuing to mention/repeating the same things (questioning of other posters motives) over and over and expecting a different outcome is also the definition of stupidity. Us (can I "us"e this?) Longs (including "you"), "we" are all PISSED and DISGUSTED about how things have enveloped, but you know what sh^t happens. Get over it! Don't invest want you cant afford to lose. Those that have different motives on this board, big fn deal...life is not butterflies and rainbows, right?
Brekken will present tomorrow afternoon, the market will do what it does, and we can play as we see fit and post what we (there is that "we" again) wish. Just get over posting the same BS..."we" get it...your questioning of certain posters is noted!!
The quick brown fox jumps over the lazy dog.
Give it a rest already. he, she, we, me.
Amazing, how everything can be construed. EBS has the right to do what ever he feels. CP has the right to defend himself and write what he wishes. You both provide excellent insight, theories, some right, some wrong. Who the F&^% cares. To each his own. Just like everyone on this board writing what they want.
I prefer to provide you all with a joke:
Why did God create stock analysts?
In order to make weather forecasters look good.
Can we predict better? I believe we have and will all be fat and happy!!
Hysterical. I must admit that one takes the cake.
Inside the Alzheimer's Lab: Interviews With Our Researchers - See more at: http://curealz.org/2014/03/inside-alzheimers-lab-interviews-our-researchers#sthash.fdpMAn2R.dpuf
3rd video has Tanzi
Posted: Mar. 21, 2014
http://curealz.org/2014/03/inside-alzheimers-lab-interviews-our-researchers
GSK missed...hopping on flight posting quickly.
LEXINGTON, Mass., Mar 20, 2014 (BUSINESS WIRE) -- Agenus Inc. AGEN +0.23% today announced that GlaxoSmithKline’s GSK -1.72% MAGRITi study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3ii cancer immunotherapeutic trial in non-small cell lung cancer patients, which contains Agenus’QS-21 Stimulon® adjuvant, did not meet its first or second co-primary endpoint. The study did not significantly extend the disease-free survival (DFS)iii period when compared to placebo in the overall MAGE-A3 positive patients or patients who did not receive chemotherapy.
GSK announced that it will continue the study until an analysis of the third co-primary endpoint is complete. The third co-primary endpoint is based on predefined criterion that was discussed with regulatory authorities. This analysis is based on gene signature and designed to prospectively identify MAGE-A3 positive patients who may benefit more from treatment. If further analysis shows that the predefined gene signature subset data are successful, there is the potential for regulatory filing. GSK anticipates that these data should be available in 2015. Until then, GSK will remain blinded to all safety and efficacy data.
Keep your friends close, keep your enemies closer.
Why? Ever think it may be that the "community" is done with his antics and he is set to be truly embarrassed in front of those whom he continually writes bad press about?
I believe it may just be poetic and public suicide for him.
The funny part is, he has no clue. He really believes, "I am important to the biotech world."
That is the post of the day!!
Soon we will be using the term..."Bavivindicated".
or when we continue to see/hear results through multiple combinations...it was "Bavilicious".
ha...just needed a little humor...
Spot on!!! That is exactly why you present positive information globally in the span of weeks. it is the ole, they tell two friends, they tell two friends...happens at the institutional level as well. Wait till the elevator guy, the bell hop, and the driver gets the news...then it goes viral.
not yet